Aravind Eye Care System, Madurai, India.
Am J Ophthalmol. 2012 Dec;154(6):934-939.e1. doi: 10.1016/j.ajo.2012.06.001. Epub 2012 Sep 5.
To compare the clinical course of Nocardia species keratitis with keratitis resulting from other bacterial organisms and to assess the effect of corticosteroids as adjunctive therapy using data collected from the Steroids for Corneal Ulcers Trial.
Subgroup analysis of a randomized controlled trial.
setting: Multicenter randomized controlled trial. study population: Five hundred patients with bacterial keratitis randomized 1:1 to topical corticosteroid or placebo who had received at least 48 hours of topical moxifloxacin. intervention/observation procedure: Topical prednisolone phosphate 1% or placebo and clinical course of Nocardia keratitis. main outcome measures: Best spectacle-corrected visual acuity and infiltrate or scar size at 3 months from enrollment.
Of 500 patients enrolled in the trial, 55 (11%) had a Nocardia corneal ulcer. Patients with Nocardia ulcers had better presentation visual acuity compared with non-Nocardia ulcers (median Snellen visual acuity, 20/45, compared with 20/145; P < .001) and comparable 3-month visual acuity (median, 20/25, vs 20/40; P = .25). Nocardia ulcers had approximately 2 lines less of improvement in visual acuity compared with non-Nocardia ulcers (0.21 logarithm of the minimal angle of resolution; 95% confidence interval, 0.09 to 0.33 logarithm of the minimal angle of resolution; P = .001). This difference may reflect the better starting visual acuity in patients with Nocardia ulcers. In Nocardia ulcers, corticosteroids were associated with an average 0.4-mm increase in 3-month infiltrate or scar size (95% confidence interval, 0.03 to 0.77 mm; P = .03).
Nocardia ulcers responded well to treatment. They showed less overall improvement in visual acuity than non-Nocardia ulcers, but had better presentation acuity. Corticosteroids may be associated with worse outcomes.
比较诺卡氏菌角膜炎与其他细菌性角膜炎的临床病程,并利用类固醇治疗角膜溃疡试验(Steroids for Corneal Ulcers Trial)的数据评估皮质类固醇作为辅助治疗的效果。
随机对照试验的亚组分析。
研究场所:多中心随机对照试验。研究人群:500 例细菌性角膜炎患者按 1:1 比例随机分为局部皮质类固醇或安慰剂组,所有患者均接受了至少 48 小时的局部莫西沙星治疗。干预/观察程序:局部磷酸泼尼松龙 1%或安慰剂和诺卡氏菌角膜炎的临床病程。主要观察指标:入组后 3 个月时最佳矫正视力和浸润或瘢痕大小。
在该试验中纳入的 500 例患者中,有 55 例(11%)患有诺卡氏菌角膜溃疡。与非诺卡氏菌溃疡相比,诺卡氏菌溃疡患者的就诊视力更好(中位数斯耐伦视力,20/45,对比 20/145;P<.001),且 3 个月时的视力相当(中位数,20/25,对比 20/40;P=.25)。与非诺卡氏菌溃疡相比,诺卡氏菌溃疡患者的视力改善约少 2 行(最小分辨角对数视力的 0.21;95%置信区间,0.09 至 0.33 对数最小分辨角视力;P=.001)。这种差异可能反映了诺卡氏菌溃疡患者更好的初始视力。在诺卡氏菌溃疡中,皮质类固醇与 3 个月时浸润或瘢痕大小平均增加 0.4mm(95%置信区间,0.03 至 0.77mm;P=.03)有关。
诺卡氏菌溃疡对治疗反应良好。与非诺卡氏菌溃疡相比,它们的整体视力改善程度较低,但就诊时视力较好。皮质类固醇可能与较差的结果有关。